Literature DB >> 17581886

Renal artery stenosis: cost-effectiveness of diagnosis and treatment.

Debby van Helvoort-Postulart1, Carmen D Dirksen, Patricia J Nelemans, Abraham A Kroon, Alfons G H Kessels, Peter W de Leeuw, G Boudewijn C Vasbinder, Jos M A van Engelshoven, M G Myriam Hunink.   

Abstract

PURPOSE: To use a decision analytic model to determine the cost-effectiveness of performing diagnostic digital subtraction angiography (DSA), computed tomographic (CT) angiography, or magnetic resonance (MR) angiography or proceeding immediately to tentative percutaneous revascularization in patients suspected of having renovascular hypertension.
MATERIALS AND METHODS: With use of a Markov-Monte Carlo decision model, cost-effectiveness analysis was performed from a societal perspective. Data were derived from the Renal Artery Diagnostic Imaging Study in Hypertension and from published literature. The base-case analyses were used to evaluate a 50-year-old patient with a diastolic blood pressure higher than 95 mm Hg and one or more clinical clues suggestive of renovascular hypertension. Outcome measures were quality-adjusted life-year (QALY), lifetime costs, and incremental cost-effectiveness.
RESULTS: For a 50-year-old male patient, immediate tentative revascularization was the least costly (euro54 415) and most effective (12.265 QALYs) strategy. For the other strategies, costs and QALYs, respectively, were euro55 570 and 12.195 for DSA, euro55 191 and 12.163 for CT angiography, and euro56 890 and 12.088 for MR angiography. For a 50-year-old female patient, costs and QALYs, respectively, were euro66 731 and 13.731 for MR angiography, euro63 970 and 13.749 for CT angiography, and euro63 079 and 13.902 for DSA. Immediate tentative revascularization yielded more QALYs (13.937) and was more costly (euro63 329) than DSA. The incremental cost-effectiveness ratio was euro7143 per QALY. As the prior probability increased, use of a more invasive diagnostic imaging strategy became justified. Also, the sensitivities of CT angiography and MR angiography and the costs of DSA influenced the results.
CONCLUSION: Given currently accepted incremental cost-effectiveness ratios, immediate tentative percutaneous revascularization is a cost-effective strategy for the diagnosis of renal artery stenosis. Management decisions should be conditional on the prior probability.

Entities:  

Mesh:

Year:  2007        PMID: 17581886     DOI: 10.1148/radiol.2442060713

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

1.  How to include informal care in economic evaluations.

Authors:  Renske J Hoefman; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

Review 2.  Newer CT applications and their alternatives: what is appropriate in children?

Authors:  R Paul Guillerman
Journal:  Pediatr Radiol       Date:  2011-08-17

3.  Screening for significant atherosclerotic renal artery stenosis with a regression model in patients undergoing transradial coronary angiography/intervention.

Authors:  Li-jin Pu; Ying Shen; Rui-yan Zhang; Qi Zhang; Lin Lu; Feng-hua Ding; Jian Hu; Zheng-Kun Yang; Wei-feng Shen
Journal:  J Zhejiang Univ Sci B       Date:  2012-08       Impact factor: 3.066

4.  Management of renal artery stenosis: 2010.

Authors:  William R Colyer; Christopher J Cooper
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

5.  relationship between distribution of coronary artery lesions and renal artery stenosis in patients undergoing simultaneous coronary and renal angiography.

Authors:  Negar Salehi; Ata Firouzi; Arash Gholoobi; Farshad Shakerian; Hamid-Reza Sanati; Mojde Nasiri Ahmadabadi; Masoud Moradi
Journal:  Clin Med Insights Cardiol       Date:  2011-03-20

Review 6.  Cost-effectiveness modelling in diagnostic imaging: a stepwise approach.

Authors:  Anna M Sailer; Wim H van Zwam; Joachim E Wildberger; Janneke P C Grutters
Journal:  Eur Radiol       Date:  2015-05-24       Impact factor: 5.315

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.